CKM and melanoma: To assess the therapeutic potential of type 1‐polarized dendritic cell therapy integrated with tumor‐selective chemokine modulation (CKM: IFN‐α‐2b rintatolimod and celecoxib) in PD‐1/PD‐L1‐refractory melanoma patients.